Table 1.

Leishmanin skin indurations (mm) and IFN-γ (pg/ml) levels at screening and during the post-vaccination follow-up visits.

Vaccination groups
Screening and follow-up days	Group 1	Group 2	Group 3	Group 4
Day 0
″LST mm	00	00	00	00
″IFN-γ picrogram/ml
Day 45
″LST mm	9·0 ± 3·5/9*	6·6 ± 4·1/6**	9·6 ± 4·2/10*	4·5 ± 4·8/5
″IFN-γ picrogram/ml	692 ± 663/1209	690 ± 478/670	930 ± 506/1263	547 ± 456/410
Day 90
″LST mm	9·3 ± 3·7*	8·6 ± 2·2/9*	10·4 ± 3·2/10*	5·8 ± 4·8/6**
″IFN-γ picrogram/ml	501 ± 472/193	236 ± 419/48	348 ± 479/119	117 ± 208/31

Continuous variables were expressed as mean ± s.d./median.

^*P < 0·01;

^**P < 0·03.